Skip to content

Study · Animal study (in vivo) · mouse · 2025

3 results

Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.

Augustin R, Oldenburger A, Baader-Pagler T, Zimmermann T, Borghardt J, Hecksher-Sørensen J, Baljuls A, Reindl W, Krawczyk B, Martel E, Brennauer A, Peters S, Grube A, Rudkjaer LB, Haebel P

Molecular metabolism5 Jul 2025Cited by 5 (Europe PMC)

PMID40619099 (opens in a new tab)PMCIDPMC12311552 (opens in a new tab)DOI10.1016/j.molmet.2025.102205 (opens in a new tab)PepBankPUB-40619099
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice, survodutide alone reduced bodyweight by 17%.

    In plain wordsIn mice with diet-induced obesity, survodutide alone lowered body weight by 17%.

    Peptide
    Survodutide
    Outcome
    DecreaseBodyweight reduction with survodutide alone
    Study

    mousen: not reported in source

    diet-induced obese mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Bodyweight reduction
    17%
    survodutide alone

    Source sentences

    Summary
    Significant bodyweight reductions were not observed with BI 1820237 alone in diet-induced obese mice, however combination with survodutide led to bodyweight reduction of 22% which was significantly (p < 0.01) greater than the 17% bodyweight reduction with survodutide alone.

Studies that did not test the peptide alone2

In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Survodutide.

  1. 02AnimalNot a test of Survodutide aloneAnimal study (in vivo)Efficacy outcome

    In diet-induced obese mice, survodutide combined with BI 1820237 reduced bodyweight by 22%, significantly more than the 17% with survodutide alone.

    In plain wordsIn mice with diet-induced obesity, survodutide plus BI 1820237 lowered body weight by 22%, more than survodutide alone (17%).

    Peptide
    Survodutide
    Outcome
    DecreaseBodyweight reduction with survodutide plus BI 1820237
    Study

    mousen: not reported in source

    diet-induced obese mice
    Comparator
    Survodutide alone
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Bodyweight reduction
    22%
    survodutide plus BI 1820237
    Bodyweight reduction
    17%
    survodutide alone

    Source sentences

    Summary
    Significant bodyweight reductions were not observed with BI 1820237 alone in diet-induced obese mice, however combination with survodutide led to bodyweight reduction of 22% which was significantly (p < 0.01) greater than the 17% bodyweight reduction with survodutide alone.

    In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Survodutide.

  2. 03AnimalNot a test of Survodutide aloneAnimal study (in vivo)Mechanism

    In regression-based interaction analysis, BI 1820237 increased the efficacy of survodutide by 265% at an ED50 of 11.7 nmol/kg across dose combinations.

    In plain wordsIn mice, adding BI 1820237 boosted the weight-lowering effect of survodutide by 265% in an interaction analysis.

    Peptide
    Survodutide
    Outcome
    IncreaseSynergy of BI 1820237 with survodutide (regression interaction analysis)
    Study

    mousen: not reported in source

    diet-induced obese mice
    Comparator
    Survodutide alone
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Measurements

    Efficacy increase
    265%
    survodutide plus BI 1820237
    ED50
    11.7 nmol/kg
    dose combinations

    Source sentences

    Summary
    Regression-based interaction analysis demonstrated that BI 1820237 increased the efficacy of survodutide by 265% at an ED50 of 11.7 nmol/kg over a range of dose combinations.

    In this study, Survodutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Survodutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.